The next focusIR Investor Webinar takes places on 14th May with guest speakers from Blue Whale Growth Fund, Taseko Mines, Kavango Resources and CQS Natural Resources fund. Please register here.
Crl it's a bit more complicated than you'd think, actually a lot more, check out the threads on the Theradiag on the Bourse forum. https://www.boursorama.com/bourse/forum/1rPALBIO/detail/461473855/
You can say no to selling your shares but just end up left behind
Can't find it but there's a good one explaining how non-sold shares turn zombie, still listed but free float without securities or something and so probably valued less than the takeover offer price in the afterworld.
DRB, it was an example of the lousy language NCYT use in RNS and updates, they said 'closing' instead of 'rebranding' Primer Design, most negative language possible.
The technology and patents of a load of companies are pretty much what Novacyt is with a bit of manufacturing thrown in. IT-IS is a very sellable asset as it comes with Novacyt as an existing customer defo worth quite a bit more than the takeover price.
Not sure you can predict the SP, surely it's going with the ebb and flow of the market and sector, unfortunately more flow than ebb atm.
It's only a couple of months since they hit the panic button so can't expect much more than a reassurance that things are in hand. An ideal opportunity for positivity and enthusiasm for the future, but NCYT don't do positivity atm.
"Baby you'll have to do some research,myself and posters on this board have been asking that question for the last two years.Obviously you don't know who the partner is , perhaps you'll come back and tell us when you find out."
EX, it's an idiotic question because to me as a shareholder it doesn't matter who manufactures. It's an idiotic question because it concerns the day to day running of the business, no concern to a shareholder. It's an idiotic question because only idiots would spend two years trying to find the answer.
I'm mortified for you and the other idiots who believe you are intelligent because you have spent two years trying to find out who manufactures NCYTs' LTFs' (They do their own development btw (not sure if you worked that out)) yet at the same time some of the gang think the PrimerDesign business unit was been shut and everyone made redundant, you lot are clowns
crl we're describing a similar issue, 'negative language' was shorthand for to describe RNSs' bleached of any positivity whatsoever. And positivity from the BoD is all I want, no need to explain stuff in too much detail I'm only a shareholder, just make sure everything is delivered 100% sugar coated and wrapped in wonderfulness.
crl, you're being to kind, recent RNS and presentations have gone overboard with negative language, instead of saying they were shelving unprofitable products and rebranding all products as Novacyt, they announced they were closing Lab21 HC and PrimerDesign, so we had numpties on here stating there would be redundancies (and confusion when, guess what, PrimerDesign launched new LFTs badged as Novacyt) that language cannot help the SP.
BoDs make bad business decisions, external factors influence performance, these things happen in life. But why purposely use such lousy language in comms is a mystery
yesterdays jump was an 'educated' punt, NCYT is dual listed with a sterling crash, 52 week low, trading update due, Bio announcing another takeover, someone thought things were lining up and others joined in. Next few days will be interesting, will any increase stick or will the SP erode away as before.
I did say 'little or none' there is some. Cash only matters when you spend it, Debt doesn't matter much as long as you show it's managed, atm 10-20% of companies in Europe are zombies, how many can you name?
Re M&A, it's repeated on here like a mantra, it's a verb not a noun, it can be done well or it can be done badly. GM, who everyone seems to hate for some reason, was an M&A specialist who prior to his reverse takeover of Novacyt built Lab21 with several acquisitions. And before Lab21 he already had a good CV. So, yippee he's gone, sorry to hear no-one likes the new guy either, but more importantly who on the BoD has the smarts to find and execute M&A projects (considering recently a website relaunch was/is an embarrassment, product launches anonymous and/or confusing, a failed AGM attempt. etc etc )
Some positive language for a change would be nice, but don't expect green shoots just yet, the ship is only starting to turn.
HC there is little or no relation between MCap and cash in the bank. The cash is only available to the business and if the business isn't using it than the money is not really important. Once they spend the money the SP will reflect if it was a good or bad investment until then it's a bit schrodinger's cat.
Really don't know what you expect in the update, they rolled out the business pivot internally in July, released a few products and we're coming out of Summer, not much business happens in Summer for any sector.
A lot of the SP damage is self-inflicted but a chunk of the drop is driven by external factors and cannot be blamed on the BoD
HC, the drop been 'excessive' is an opinion. Others disagree.
How can you expect 'green shoot's ' after 1Q.
The rise which is now fizzling out was external factors, Bio's M&A, sterlings drop etc coupled with NCYT current low SP and general malaise
Can't be good news on revenue as it's only Q3. Q1 and Q2 were a disaster
A takeover of NCYT at this SP is bad news for me.
Only possible good news is NCYT M&A, which is unlikely.
Guessing some folk added 2+2 and got 7. I think this pump will fizzle out soon, it's too soon for it to be based on anything real, it'll happen, but not for a Q or 2
Looks like Larry is right, Theradiag shares suspended today.
Someone on the Bourse did the maths
"with theradiag's suspension, there is no longer any suspense.
I suppose that there is an emergency board at theradiag which must decide on the offer...and which will support it given the composition
In any case, it is an excellent operation for BIO if it is done because in addition to a positive treasury of €5 million, theradiag, which is now profitable, has a carryforward tax deficit of €36 million.
With the 28% bought at a discount, with 25-30 M€ in cash in addition to their 28%, they buy growth, get their hands on 9.5 M€ in tax savings, synergies, and a global leader in theranostics"
IF you actually own any shares I'd advise you to look up your rights. Those questions are childish you do not have any right to ask those questions .
You've been reading and believing the 'Mandy' emails on here.
Try coming up with some proper Investor questions
We've not had a chart for a while.....
thread on the bourse https://www.boursorama.com/bourse/forum/1rPALNOV/detail/461423009/
"Some call it exponential.
Successive steps decrease roughly by a factor of 1.4.
The next level would be around €0.72 if the descent continues.
But I have absolutely no idea if the descent will continue.
TA is obviously of no help, except to recall the past without any guarantee that the tendencies that one believes to perceive there will continue almost identically.
The so-called fundamentals don't help either; management's forecasts are a weak turnover and still, not for now, knowing that this turnover is not sufficient to produce a positive result.
Past trading performance is also not very encouraging; it is repeatedly recalled here that, even at the height of the Covid, Novacyt did not sell much.
Getting in now, at €1, remains a bet, playable of course, but only a bet on luck and the conjunctions of phenomena that escape us. It's tempting but not really reasonable."
"It is an interesting observation.
Assuming the displayed averages are correct, the drop per step is on average 27.7% (-32% / -25% / -26%)
You would think that these are either calculation algorithms or a nice job of the order book? By who ? We then refer to Logos.
We also note that the volatility in stages has decreased significantly. Which makes things less interesting.
In the meantime, should we fall back on other indicators perhaps?"
Unless there's a surprise mutation around the corner Covid is now on a par with flu and it's a mature marketplace with plenty of competition. That ending was always on the cards, the quirky bit is how Covid has become a dirty word, the surprising bit is the complete lack of gov interest or investment in this sector anywhere posy Covid.
The West pivoted from the need for massive investment in science to prevent future pandemics to pumping zillions into a war instead. Almost as if the science bit was too difficult so they opted for a good old war.